SLNSW-First-Line Crizotinib versus Chemotherapy in ALK-...-TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Full title: First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

Author/creator: PROFILE 1014 Investigators, Solomon, Benjamin J, Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Tursi, Jennifer, Blackhall, Fiona.

Call Numbers:

Record Identifier: TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

Language: English

Formats: Articles

Publishers: Waltham, MA: Massachusetts Medical Society

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    Record identifier

    TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

    Share

    First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

    First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    Full title

    First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

    Author / Creator

    PROFILE 1014 Investigators ; Solomon, Benjamin J ; Mok, Tony ; Kim, Dong-Wan ; Wu, Yi-Long ; Nakagawa, Kazuhiko ; Mekhail, Tarek ; Felip, Enriqueta ; Cappuzzo, Federico ; Paolini, Jolanda ; Usari, Tiziana ; Iyer, Shrividya ; Reisman, Arlene ; Wilner, Keith D ; Tursi, Jennifer ; Blackhall, Fiona

    Publisher

    Waltham, MA: Massachusetts Medical Society

    Journal title

    The New England journal of medicine, 2014, Vol.371 (23), p.2167-2177

    Record Identifier

    TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma/drug therapy/mortality Adult Aged Analysis Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use Appetite Biological and medical sciences Biomedical research Cancer Carboplatin Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung/drug therapy/mortality Cardiovascular & respiratory systems Care and treatment Chemotherapy Cisplatin Cisplatin - administration & dosage Comparative analysis Comparative studies Crizotinib Diarrhea Disease-Free Survival Dosage and administration Edema Fatigue Female General aspects Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Guanine/administration & dosage/analogs & derivatives Human health sciences Humans Inhibitor drugs Intravenous administration Kaplan-Meier Estimate Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms/drug therapy/mortality Lungs Male Medical sciences Metastasis Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nausea Non-small cell lung carcinoma Patients Pemetrexed Platinum Pneumology Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein Kinase Inhibitors/adverse effects/therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrazoles/adverse effects/therapeutic use Pyridines - adverse effects Pyridines - therapeutic use Pyridines/adverse effects/therapeutic use Quality of life Receptor Protein-Tyrosine Kinases - antagonists & inhibitors Risk factors Sciences de la santé humaine Systèmes cardiovasculaire & respiratoire Treatment outcome Tumors Tumors of the respiratory system and mediastinum Vomiting

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_liege_orbi_v2_oai_orbi_ulg_ac_be_2268_176692

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    About resource >

    View in old catalogue

    Connecting people and collections